literature

HIV mutation literature information.

Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.

PMID: 25926858 2014 AIDS research and therapy

Result: One patient (patient 14 in Table 4) showed the transient development of the N[t]RTI RAM L74I/L and the NNRTI RAM P225H/P at the Week 16 visit, which were not detected at the subsequent Week 48 visit analysis as shown in Table 4.

Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.

PMID: 23469241 2013 PloS one

Table: L74V/I

Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.

PMID: 23480551 2013 Clinical microbiology and infection

Abstract: The concordance rates between the RFMP and direct sequencing assays for the examined codons were 97% (K65R), 97% (T69Ins/D), 97% (L74VI), 97% (K103N), 96% (V106AM), 97% (Q151M), 97% (Y181C), 97% (M184VI) and 94% (T215YF) in the reverse transcriptase coding region, and 100% (D30N), 100% (M46I), 100% (G48V), 100% (I50V), 100% (I54LS), 99% (V82A), 99% (I84V) and 100% (L90M) in th

Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009).

PMID: 23585827 2013 PloS one

Abstract: Major mutations in reverse transcriptase included K65R(n = 1), L74I(n = 1), K103N(n = 19), V106M(n = 4), Y181C(n = 2), M184V(n = 4), and K219E/R(n = 2).

Result: The following mutations were detected in only one sample each: M46L and I85V (protease); K65R, L74I, K219E/R, and K101E (reverse transcriptase) (Figure 4).

Table: L74I

Transmitted HIV drug resistance in treatment-naive Romanian patients.

PMID: 23592112 2013 Journal of medical virology

Result: M184V, the 3TC-selected mutation was identified in three HIV resistant strains, alone in two cases and together with all the above mentioned type II TAMs, as well as other NRTI conferring resistance mutations (T69D and L74I) in one case.

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

PMID: 23840622 2013 PloS one

Method: Different RT mutations at the same residue were pooled, including the NRTI-resistance mutations D67NG, K70EGQ, L74VI, M184VI, T215YF, K219QE and the NNRTI-resistance mutations K101EH, K103NS, Y188LCH, and G190ASEQ.

Result: L74VI occurred in 13/153 (8.5%) patients receiving TDF and 30/54 (55.6%) receiving ABC compared with 1.8% receiving d4T or AZT (p<0.001 for both TDF and ABC).

Result: Three mutatio

Persistence of HIV-1 transmitted drug resistance mutations.

PMID: 23904291 2013 The Journal of infectious diseases

Table: L74I

Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.

PMID: 24009694 2013 PloS one

Table: L74I

Transmitted drug resistance and phylogenetic analysis of HIV CRF01_AE in Northern Vietnam.

PMID: 21620998 2012 Infection, genetics and evolution

Abstract: Four drug resistance mutations; Y181C, L210W, L74I and V75M, were found in four different patients, giving a prevalence of 6.3% (4/63).

In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.

PMID: 22564967 2012 Antiviral research

Abstract: At week 88 F121Y was no longer detected, L74I and T97A were maintained and Y143R emerged.

Abstract: The emergence of F121Y was observed at week 32 and 40, alongside with L74I, T97A, Q137H and V151I.

Browser Board

Co-occurred Entities

Filtrator